PhaseBio Expands Executive Management Team
October 24 2019 - 4:01PM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for cardiopulmonary diseases,
today announced the expansion of its executive management team with
the appointment of Kristopher L. Hanson as Vice President, Head of
Legal and Glen Burkhardt as Vice President of Human Resources.
“PhaseBio has achieved critical milestones this
year and is making solid progress in the advancement of PB2452, a
novel agent for the reversal of the antiplatelet activity of
ticagrelor,” said Jonathan P. Mow, Chief Executive Officer of
PhaseBio. “These additions to our management team allow us to more
efficiently prepare for the submission of a Biologics License
Application for PB2452 and for potential accelerated approval and
commercial launch. We are delighted to welcome Kris and Glen, two
seasoned leaders with extensive biopharmaceutical industry
experience, to the team.”
Mr. Hanson will oversee and manage the company’s
legal affairs, including support of clinical development efforts,
strategic and licensing transactions, corporate governance,
compliance and other key areas. Prior to joining PhaseBio, Mr.
Hanson served as Vice President, Legal & Compliance and Head of
Human Resources for Nalpropion Pharmaceuticals where, as a member
of the company’s executive management team, he had responsibility
for the company's legal, compliance and human resources functions.
Prior to Nalpropion, he served as Vice President and Assistant
General Counsel for Orexigen Therapeutics and before that worked in
senior legal roles at Lytx, Cricket Communications and SAIC. He
received his JD from UCLA School of Law and his BA from Georgetown
University.
With more than 25 years of human resources
experience in the life sciences industry, Mr. Burkhardt will
oversee the human resources department of PhaseBio. Prior to
joining PhaseBio, he was a founding principal for Landscope Life
Science Consulting, LLC. He has also served as Vice President of
Human Resources for Hologic, Inc., prior to which he was Senior
Director of Human Resources at Onyx Pharmaceuticals from 2011 until
its sale to Amgen in 2014. Earlier in his career, Mr. Burkhardt
held several human resources roles at Eli Lilly and Company,
including leadership of its global talent management function. He
received BS and BArch degrees from Ball State University and an MBA
from the Indiana University Kelley School of Business.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies to treat orphan diseases,
with an initial focus on cardiopulmonary disorders. The company’s
lead development candidate is PB2452, a novel agent for the
reversal of the antiplatelet therapy ticagrelor. PhaseBio is also
leveraging its proprietary elastin-like polypeptide (“ELP”)
technology platform to develop therapies with the potential for
less-frequent dosing and improved pharmacokinetics. PhaseBio’s
second product candidate PB1046, which is based on ELP, is a
once-weekly vasoactive intestinal peptide receptor agonist for the
treatment of pulmonary arterial hypertension.
PhaseBio is located in Malvern, PA and San Diego,
CA. For more information, please visit www.phasebio.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “anticipates,” “believes,”
“expects,” “intends,” “projects,” and “future” or similar
expressions are intended to identify forward-looking
statements.
Forward-looking statements include statements
concerning or implying the conduct or timing of our clinical trials
and our research, development and regulatory plans for PB2452,
PB1046 and our ELP research programs. Forward-looking statements
are based on management's current expectations and are subject to
various risks and uncertainties that could cause actual results to
differ materially and adversely from those expressed or implied by
such forward-looking statements. Accordingly, these forward-looking
statements do not constitute guarantees of future performance, and
you are cautioned not to place undue reliance on these
forward-looking statements.
Risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Quarterly Report on Form 10-Q for the quarter ended June 30,
2019. These forward-looking statements speak only as of the date
hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation
to update these statements except as may be required by law.
Investor Contact:John
SharpPhaseBio Pharmaceuticals, Inc. Chief Financial Officer(610)
981-6506john.sharp@phasebio.com
Media Contact:Gina Cestari6
Degrees(917) 797-7904gcestari@6degreespr.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Aug 2024 to Sep 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Sep 2023 to Sep 2024